Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/33253
Type
ArticleCopyright
Open access
Embargo date
2019-11-28
Collections
- INI - Artigos de Periódicos [3465]
Metadata
Show full item record
IMMUNOGLOBULINS G, M, AND A AGAINST SPOROTHRIX SCHENCKII EXOANTIGENS IN PATIENTS WITH SPOROTRICHOSIS BEFORE AND DURING TREATMENT WITH ITRACONAZOLE.
Sporothrix schenckii
Immunoglobulin G
Immunoglobulin M
Immunoglobulin A
Itraconazole
Affilliation
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia. Rio de Janeiro, RJ, Brasil / Albert Einstein College of Medicine. Department of Medicine. Division of Infectious Diseases. New York, NY, USA.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia. Rio de Janeiro, RJ, Brasil
Albert Einstein College of Medicine. Department of Medicine. Division of Infectious Diseases. New York, NY, USA / Albert Einstein College of Medicine. Department of Microbiology and Immunology. New York, NY, USA.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia. Rio de Janeiro, RJ, Brasil
Albert Einstein College of Medicine. Department of Medicine. Division of Infectious Diseases. New York, NY, USA / Albert Einstein College of Medicine. Department of Microbiology and Immunology. New York, NY, USA.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Serviço de Micologia. Rio de Janeiro, RJ, Brasil.
Abstract
Sporotrichosis is an important subcutaneous mycosis, with an increasing worldwide incidence. However, few
data are available regarding the immunological aspects of Sporothrix schenckii infection, particularly the
humoral responses to the fungus. In this study we measured immunoglobulin G (IgG), IgM, and IgA in sera
from 41 patients with sporotrichosis before antifungal treatment and from another 35 patients with sporotrichosis during itraconazole treatment by using a recently described S. schenckii exoantigen enzyme-linked
immunosorbent assay (ELISA). More than 95% of patients had detectable IgA antibodies, and more than 85%
had IgM and IgG antibodies before treatment. The number of patients with IgG antibodies increased to 91%
during treatment. Conversely, significantly fewer samples from treated patients were positive for IgM (71%)
and IgA (89%). Overall, 78% of patients had detectable levels of all isotypes tested at diagnosis, and this
percentage dropped to 62.9% in patients receiving itraconazole. Testing of all three isotypes improved the
sensitivity; at least two isotypes were detected in 93% of patients before and 89% after treatment. The reactivity
of 94 sera from patients with other diseases and healthy individuals was also tested. Cross-reactivity occurred
in 33% of the heterologous sera. Most of them were positive only in one isotype, 8.5% were positive for at least
two isotypes, and only one serum (1.1%) was positive for the three isotypes. Antibodies produced during S.
schenckii infection are diverse, and we demonstrate that an exoantigen ELISA for the detection of combinations of IgA, IgG, and IgM antibodies is a highly sensitive and specific diagnostic assay for sporotrichosis.
Keywords
SporotrichosisSporothrix schenckii
Immunoglobulin G
Immunoglobulin M
Immunoglobulin A
Itraconazole
Share